Meridian Co., Ltd.
OTC Bulletin Board : MRDAF

Meridian Co., Ltd.

May 24, 2006 09:00 ET

Meridian Co.'s Aggressive Expansion Plan has Commenced Through Major Pharmacy Outlets in South Korea and China

SEOUL, KOREA--(CCNMatthews - May 24, 2006) - Meridian Co., Ltd. ("Meridian") (OTCBB:MRDAF) is very pleased to announce that it has entered into a preliminary distributorship agreement with a Korean beauty and health product distributor, Jang's & Parms Corporation ("J&P"), for its arterial screening device, the Digital Pulse Analyzer (DPA) on May 15, 2006.

In this contract J&P has the exclusive right to sell the DPA to pharmacies in Korea and has marketing and distributorship rights in China. This preliminary agreement specifies that J&P must complete the sale of minimum 100 DPA within 5 months in order for two parties to sign for full distributorship agreement.

J&P, has been successful with its own brand, and is currently distributing its beauty and health products to 5500 of 18,000 pharmacies in Korea. J&P also established a sales network in China in 2002.

J&P expects sales of approximately US$1.3 million in revenue derived from sales of the DPA in 2006 and US$2.3 million in sales revenue in 2007.

More About: Digital Pulse Analyzer ("DPA")

The "DPA" accurately measures the elasticity of small and large arteries and provides health care practitioners with critical information regarding arterial aging. This FDA approved device is inexpensive, non-invasive, and can provide results in minutes. Accumulating evidence suggests that abnormalities in the pulsatile characteristics of arteries occur early in the disease process associated with increased cardiovascular risk, and can be favorably modified by therapeutic interventions.

The Company feels that use of the "DPA" can help caregivers reduce cardiovascular disease in their patient populations through early detection and prevention, and ultimately assist to decrease the associated financial costs placed on the health care industry. Cardiovascular disease is the #1 killer in the United States with an estimated economic cost of approximately $298 billion.

More About: Meridian

Meridian is an established leader in the research/development, manufacturing, and sales of integrative medical diagnostic equipment. The company sells its products and equipment to a wide array of customers in the global health care industry. The company presently holds a total of 18 worldwide patents on its technology, and has received FDA, as well as other international regulatory approvals for many of its products.

Meridian is committed to the ongoing global research and advancement of integrative medical products that contribute to the better health of humanity.

On Behalf of the Board of Directors,

Hyeon Seong Myeong, President

This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the company.

Contact Information